Rightangled Ltd, Coventry, West Midlands, UK.
Rightangled Ltd, Birmingham, West Midlands, UK.
Am J Cardiovasc Drugs. 2018 Aug;18(4):259-269. doi: 10.1007/s40256-018-0267-2.
Pharmacogenetics is an emerging area of medicine, and more work is needed to fully integrate it into a clinical setting for the benefit of patients. Genetic markers can influence the action of many drugs, including those that prevent and treat cardiovascular conditions. Genotyping is not yet commonplace, but guidelines are being put in place to help practitioners determine the effect a genetic marker may have on certain drugs. With advancements in genetic technology and falling costs, genotyping could be available to all patients via a simple saliva test. This would be a cost-effective way for practitioners to determine the most effective treatment for individuals, reducing "trial and error," adverse effects, and rehospitalization rates and increasing patient compliance. Cardiovascular diseases are the leading causes of death worldwide, so using the most effective medication to treat or prevent them is of utmost importance in reducing incidence and mortality.
药物遗传学是医学领域的一个新兴领域，需要做更多的工作将其充分整合到临床环境中，以造福患者。遗传标记可以影响许多药物的作用，包括预防和治疗心血管疾病的药物。基因分型尚未普及，但正在制定指南，以帮助从业者确定遗传标记对某些药物的影响。随着基因技术的进步和成本的降低，通过简单的唾液测试，基因分型可能对所有患者都可用。对于从业者来说，这是一种具有成本效益的方法，可以确定针对个体的最有效治疗方法，减少“试错”、不良反应、再住院率，并提高患者的依从性。心血管疾病是全球死亡的主要原因，因此，使用最有效的药物来治疗或预防这些疾病对于降低发病率和死亡率至关重要。
